Sai Parenteral‘s is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates across two segments: (1) Branded Generic Formulations and (2) Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.

Branded Generic Formulations refer to off-patent pharmaceutical products marketed under proprietary brand names. The CDMO segment provides end-to-end services. These include product development and validation batches, which are trial runs to ensure consistent manufacturing quality. In addition, the segment handles dossier compilation, prepares regulatory documentation, manages international regulatory filings for product...

• 

  (23-Mar-26 20:05)

  Powerica
• 

  (19-Mar-26 15:36)

  Amir Chand Jagdish Kumar (Exports)
• 

  (19-Mar-26 19:37)

  Central Mine Planning & Design Institute
• 

  (13-Mar-26 17:10)

  GSP Crop Science

• IPO Centre - IPO News   (30-Mar-26 10:45)

  Sai Parenteral’s IPO ends with 1.05 times subscription

• IPO Centre - IPO News   (27-Mar-26 17:33)

  Sai Parenteral’s IPO subscribed 1.05 times

• IPO Centre - IPO News   (25-Mar-26 17:05)

  Sai Parenteral’s IPO subscribed 41%

• IPO Centre - IPO News   (24-Mar-26 17:11)

  Sai Parenteral’s IPO subscribed 4%